Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole ER vs Esomeprazole in Erosive GERD
NCT00658528Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of rabeprazole in erosive gastroesophageal reflux disease (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks and Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks. Started Feb 2008; status: completed.
02
Drugs
rabeprazole
03
Conditions
erosive gastroesophageal reflux disease
Beyond the preview
Go deeper on NCT00658528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658528.